03 Dec EB1A Extraodinary Ability Alien Case Approved For Human Monoclonal Antibody Therapeutics Researcher
EB1A Extraodinary Ability Alien Petition approved at the Texas Service Center using premium processing for Indian National who was found by USCIS to be one of the small percentage of researchers at the very top of the field of human monoclonal antibody therapeutics. The Beneficiary developed a new method to create human monoclonal antibodies that is being used by governmental organizations, private corporations and academic institutions worldwide to create human monoclonal antibodies to treat disease. Evidence submitted in support of the EB1A Extraordinary Ability Alien Petition included letters regarding the original scientific research contributions of Beneficiary and the commercial use of his research by others to develop human monoclonal antibodies, receipt of a Small Business Innovative Research Grant from the National Institutes of Health, publications in top-ranked international journals, discussion of Beneficiary’s work by other researchers and in major media, evidence of Beneficiary’s peer review activity, evidence of commercial success via patents and a licensing agreement, evidence of presenations at international conferences, and evidence that Beneficiary has served in a leading or critical role for an organization with a distinguished reputation. Beneficiary was working part-time at both a H-1B cap exempt employer and a H-1B cap subject employer and his self-filed Extraordinary Ability Alien Petition allows him to adjust his status to permanent resident without employer sponsorship, enabling him to continue his full-time equivalent work for both employers.